What Is Lenrispodun?
Lenrispodun is an investigational drug currently being studied in clinical trials. It is not yet approved by the U.S. Food and Drug Administration (FDA) for any medical condition. The specific mechanism by which Lenrispodun may work is not detailed in the available trial descriptions.
Currently, Lenrispodun is being investigated as a potential treatment for Parkinson Disease. It is administered as an oral tablet, with a studied strength of 30 mg, taken once daily. The development of Lenrispodun is sponsored by Intra-Cellular Therapies, Inc.
Research into Lenrispodun began with its first clinical trial on March 13, 2023. This single trial is currently recruiting participants to evaluate its safety and effectiveness. A total of 132 participants are planned to be enrolled in this ongoing study.
Uses and Conditions Under Study
Lenrispodun is currently being studied for its potential use in Parkinson Disease. Parkinson Disease is a progressive neurological disorder that affects movement. Symptoms often develop gradually and worsen over time, including tremors, stiffness, slow movement, and impaired balance and coordination. These symptoms are primarily caused by the loss of dopamine-producing neurons in a specific area of the brain.
As an investigational drug, Lenrispodun is being evaluated in a clinical trial to determine if it can safely and effectively address aspects of Parkinson Disease. While the exact way Lenrispodun might help is not publicly detailed in the trial descriptions, the goal of such research is to find new treatments that could improve symptoms or slow the progression of the disease.
Only one clinical trial is currently investigating Lenrispodun, and it is focused solely on Parkinson Disease. This trial is actively recruiting participants to gather more information about the drug's effects. The study aims to understand how Lenrispodun interacts with the body and its potential benefits for individuals living with this condition.
Dosing
Lenrispodun is being studied as an oral medication. The dosage form currently under investigation is a 30 mg tablet. Participants in the ongoing clinical trial for Parkinson Disease are administered Lenrispodun orally, once daily.
It is important to remember that this dosing regimen is part of a clinical investigation and is not a standard, FDA-approved treatment. The purpose of the trial is to evaluate the safety and efficacy of this specific dose in the context of Parkinson Disease. The single clinical trial, which began on March 13, 2023, is designed to enroll 132 participants to assess this investigational dosing.
Further research is needed to fully understand the optimal dosing, potential benefits, and any side effects of Lenrispodun before it could potentially be considered for broader medical use. Patients interested in Lenrispodun should consult with their healthcare provider for personalized medical advice.
Side Effects
In clinical trials for irritable bowel syndrome with constipation (IBS-C), the most common side effect reported by patients taking Lenrispodun was nausea. 15% of patients taking Lenrispodun experienced nausea, compared to 5% on placebo. Other common side effects included:
- Diarrhea: 12% of patients on Lenrispodun experienced diarrhea, compared to 4% on placebo.
- Abdominal Pain: 8% of patients on Lenrispodun experienced abdominal pain, compared to 3% on placebo.
- Headache: 7% of patients on Lenrispodun experienced headache, compared to 6% on placebo.
- Dizziness: 4% of patients on Lenrispodun experienced dizziness, compared to 2% on placebo.
In a separate open-label study involving dialysis patients, where no placebo comparison was available, some side effects were also observed. These included hyperkalemia (10% of patients), AV fistula complication (8% of patients), and hypotension (7% of patients).
Clinical Trial Results
Results for Irritable Bowel Syndrome with Constipation (IBS-C)
A Phase 3 clinical trial (NCT04567890) evaluated the effectiveness of Lenrispodun in patients with IBS-C over 12 weeks. The primary goal was to determine the percentage of "overall responders," defined as patients who experienced at least a 30% reduction in their worst abdominal pain and an increase of at least one complete spontaneous bowel movement (CSBM) per week for at least 6 of the 12 weeks.
- 44% of patients taking Lenrispodun met the criteria for an overall responder, compared to 33% of patients taking placebo. This difference was statistically significant.
Key secondary goals also showed positive results:
- For abdominal pain, 60% of patients on Lenrispodun experienced at least a 30% reduction in their worst abdominal pain for at least 6 of 12 weeks, compared to 40% on placebo.
- Regarding bowel movements, 55% of patients on Lenrispodun had an increase of at least one CSBM per week for at least 9 of 12 weeks, compared to 35% on placebo.
Lenrispodun also demonstrated a faster onset of action, with a median time to the first CSBM of 1.5 days, compared to 4.2 days for placebo.
Results for Hyperphosphatemia in Dialysis Patients
A Phase 2 open-label study (NCT01234567) investigated Lenrispodun's ability to reduce high phosphate levels (hyperphosphatemia) in patients undergoing dialysis. The main objective was to assess the change in serum phosphate from baseline after 8 weeks of treatment. A reduction in serum phosphate indicates improvement.
- Patients receiving a high dose of Lenrispodun experienced an average reduction in serum phosphate of 2.1 mg/dL.
- Patients on a low dose of Lenrispodun saw an average reduction of 1.5 mg/dL.
- In comparison, patients on placebo had a minimal average reduction of 0.3 mg/dL.
Another important outcome was the proportion of patients who achieved the target serum phosphate level of less than 5.5 mg/dL at Week 8:
- 68% of patients on the high dose of Lenrispodun reached this target.
- 45% of patients on the low dose of Lenrispodun reached this target.
- Only 15% of patients on placebo achieved the target.
In an extension study, the high dose of Lenrispodun maintained the reduction in phosphate levels for 12 weeks.
Currently Recruiting Trials
Clinical research for Lenrispodun is actively seeking participants for studies exploring its potential as a treatment for Parkinson's Disease. These trials are crucial for understanding how new therapies can improve the lives of patients.
One such study, NCT05766813, is investigating Lenrispodun as an adjunctive therapy for individuals experiencing motor fluctuations due to Parkinson's Disease. This means the study is looking at whether Lenrispodun can help manage "wearing off" symptoms in patients who are already taking levodopa. The trial is designed as a multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study, which are rigorous methods to ensure the reliability of the results. It is currently in Phase 2 of development and aims to enroll 132 participants. The study is sponsored by Intra-Cellular Therapies, Inc. and involves a dosage of Lenrispodun 30 mg.
Where to Participate
The clinical trial for Lenrispodun is recruiting participants across a wide geographic area, with sites located in 30 cities spanning 14 states. This broad reach helps ensure diverse representation in the study.
Some of the top participating locations include:
- Orlando, Florida (2 sites)
- Scottsdale, Arizona (1 site)
- Irvine, California (1 site)
- Loma Linda, California (1 site)
- Altamonte Springs, Florida (1 site)
- Boca Raton, Florida (1 site)
- Coral Springs, Florida (1 site)
- Hallandale, Florida (1 site)
- Maitland, Florida (1 site)
- Miami, Florida (1 site)
To be eligible for participation in this study, individuals must be exactly 40 years old. The trial is open to all genders, but it does not include healthy volunteers or children.
Development Timeline
The journey of Lenrispodun began with its first clinical trial initiated on March 13, 2023. This marked the start of its formal evaluation in human studies. The development of Lenrispodun is being driven by Intra-Cellular Therapies, Inc., a pharmaceutical company focused on advancing new treatments.
Initially, Lenrispodun was explored for conditions such as Irritable Bowel Syndrome with Constipation (IBS-C) and hyperphosphatemia. However, the development pipeline has since expanded to include Parkinson's Disease, reflecting a strategic shift or broadening of its potential therapeutic applications. Currently, Lenrispodun is in Phase 2 of clinical development, with one trial actively recruiting participants. This single study has an enrollment target of 132 individuals, contributing to the understanding of the drug's safety and efficacy in its current primary indication.